CLAIMS:

1. A liquid pharmaceutical formulation comprising:

4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop-[f]isoindo1-2(1H)-y1)-benzamide (ST-246),

hydroxypropyl-β-cyclodextrin and/or sulfobutyl-ether-β-cyclodextrin, and

at least one pharmaceutically-acceptable ingredient.

2. The liquid pharmaceutical formulation of claim 1, wherein said at least one pharmaceutically-acceptable ingredient is a carrier, excipient, diluent, additive, filler, lubricant or binder.

3. The liquid pharmaceutical formulation of claim 1 or claim 2, wherein said hydroxypropyl-β-cyclodextrin is present in amounts from 20% to 40% by weight or has a degree of substitution from 4.0 to 8.0.

4. The liquid pharmaceutical formulation of any one of claims 1-3 having a pH from 3 to 10.

5. A process of making a liquid pharmaceutical formulation according to any one of claims 1-4, comprising:

(a) mixing ST-246 with hydroxypropyl-β-cyclodextrin and/or sulfobutyl-ether-β-cyclodextrin in a pharmaceutically-acceptable liquid carrier; and

(b) optionally filtering the mixture of step (a).

6. The process of claim 5, wherein said ST-246 is ST-246 polymorph Form I, ST-246 polymorph Form II, ST-246 polymorph Form III, ST-246 polymorph Form IV, ST-246 polymorph Form V or ST-246 polymorph Form VI.

7. The process of claim 5, wherein:

said liquid formulation is adjusted to a pH from 3 to 10,

the mixture of step (a) is brought to solubility equilibrium at a temperature of about 25°C,
the mixture of step (a) is brought to solubility equilibrium at a temperature of about 37°C, or
said ST-246 is mixed with a pharmaceutically-acceptable carrier for about 72 hours.

8. A unit dosage liquid formulation comprising:
(a) 2-20 mg/ml of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-y1)-benzamide (ST-246); and
(b) 12.5-40 mg/ml of hydroxypropyl-β-cyclodextrin.

9. The unit dosage liquid formulation of claim 8, further comprising at least one of mannitol, trehalose dehydrate, lactose monohydrate, purified water, polyethylene glycol 400, polysorbate 80, and polyethylene glycol 300.

10. The unit dosage liquid formulation of claim 8 or claim 9, having a pH range from 3.0 to 10.0 or having a total volume of 100 ml.

11. A process for preparing a water-soluble solid 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide (ST-246) pharmaceutical formulation, comprising:
(a) mixing ST-246 with hydroxypropyl-β-cyclodextrin and/or sulfobutyl-ether-β-cyclodextrin in a pharmaceutically-acceptable liquid carrier;
(b) optionally filtering the mixture of step (a); and
(c) lyophilizing said mixture.